Can Monthly Dosing With Novel GLP-1 Maintain Weight Loss?

(MedPage Today) -- At the American Diabetes Association annual meeting, updated phase II data from the VESPER program showed that patients who achieved weight loss with a weekly dose of the ultra-long-acting investigational GLP-1 agonist berobenatide...